Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATG-101 in Advanced Solid Tumors and Mature B-cell NHL
NCT04986865Phase 1Terminated
- Sponsor
- Antengene
- Start
- Dec 2021
- Primary completion
- Jan 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of ATG-101 in solid tumor and mature B-cell non-Hodgkin lymphoma, sponsored by Antengene. Primary endpoints: Adverse Events at 1 year, Serious Adverse Events at 1 year and 1 more. Started Dec 2021; status: terminated.
02
Drugs
ATG-101
03
Conditions
solid tumormature B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT04986865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04986865.